HGFR/c-MET Antibody (Korea RIBB patent anti-cMet) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28291PCP
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Korea RIBB patent anti-cMet
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
HGFR / c-Met
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for HGFR/c-MET Antibody (Korea RIBB patent anti-cMet) [PerCP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: HGFR/c-MET
Long Name
Hepatocyte Growth Factor Receptor
Alternate Names
c-MET, cMET, HGF R, MET
Gene Symbol
MET
Additional HGFR/c-MET Products
Product Documents for HGFR/c-MET Antibody (Korea RIBB patent anti-cMet) [PerCP]
Product Specific Notices for HGFR/c-MET Antibody (Korea RIBB patent anti-cMet) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...